{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:18Z","timestamp":1788848418982,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.042","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T05:23:06Z","timestamp":1314076986000},"page":"8049-8059","source":"Crossref","is-referenced-by-count":94,"title":["Evaluation of a virosomal H5N1 vaccine formulated with Matrix M\u2122 adjuvant in a phase I clinical trial"],"prefix":"10.1016","volume":"29","author":[{"given":"Rebecca J.","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S.","family":"Madhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Svindland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"S\u00e6vik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Breakwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hoschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Kristin","family":"N\u00f8stbakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit Jan","family":"Weverling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Klap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kompier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haakon","family":"Sjursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"March (13)","key":"10.1016\/j.vaccine.2011.08.042_bib0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"December (3\u20134)","key":"10.1016\/j.vaccine.2011.08.042_bib0010","first-page":"203","article-title":"Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines","volume":"191","author":"Hehme","year":"2002","journal-title":"Med Microbiol Immunol (Berl)"},{"issue":"June (9272)","key":"10.1016\/j.vaccine.2011.08.042_bib0015","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"issue":"December (25)","key":"10.1016\/j.vaccine.2011.08.042_bib0020","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2011.08.042_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.coph.2007.06.004","article-title":"Preparing for a possible pandemic: influenza A\/H5N1 vaccine development","volume":"7","author":"Keitel","year":"2007","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.vaccine.2011.08.042_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2007.00011.x","article-title":"Vaccines for an influenza pandemic: scientific and political challenges","volume":"1","author":"Haaheim","year":"2007","journal-title":"Influenza Other Respiratory Viruses"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.08.042_bib0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","article-title":"Confronting the avian influenza threat: vaccine development for a potential pandemic","volume":"4","author":"Stephenson","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"December (25)","key":"10.1016\/j.vaccine.2011.08.042_bib0040","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","author":"Greenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2011.08.042_bib0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0050","unstructured":"WHO. Tables on the clinical trials of pandemic influenza prototype vaccines. 2010 [cited 2011 1603]. Available from: http:\/\/www.who.int\/entity\/vaccine_research\/immunogenicity\/immunogenicity_table.xls."},{"issue":"August (9587)","key":"10.1016\/j.vaccine.2011.08.042_bib0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2011.08.042_bib0060","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/428948","article-title":"Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a potential priming strategy","volume":"191","author":"Stephenson","year":"2005","journal-title":"J Infect Dis"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2011.08.042_bib0065","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0264-410X(02)00632-1","article-title":"Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A\/Duck\/Singapore\/97 vaccine in a primed human population","volume":"21","author":"Stephenson","year":"2003","journal-title":"Vaccine"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2011.08.042_bib0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2011.08.042_bib0075","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/590913","article-title":"An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults","volume":"198","author":"Levie","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0080","doi-asserted-by":"crossref","unstructured":"Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011;10(April (4)):401\u20133.","DOI":"10.1586\/erv.11.25"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2011.08.042_bib0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.6.5.761","article-title":"ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines","volume":"6","author":"Drane","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0076-6879(03)73005-5","article-title":"Influenza virosomes in vaccine development","volume":"373","author":"Huckriede","year":"2003","journal-title":"Methods Enzymol"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2011.08.042_bib0095","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1016\/j.vaccine.2009.09.044","article-title":"Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice","volume":"27","author":"Madhun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0100","doi-asserted-by":"crossref","unstructured":"Pedersen G, Major D, Roseby S., Wood J, Madhun AS, Cox RJ, Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respiratory Viruses 2011;(May), doi:10.1111\/j.1750-2659.2011.00256.x.","DOI":"10.1111\/j.1750-2659.2011.00256.x"},{"issue":"July (3)","key":"10.1016\/j.vaccine.2011.08.042_bib0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jmv.10408","article-title":"Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin","volume":"70","author":"Stephenson","year":"2003","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2011.08.042_bib0110","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.08.042_bib0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0120","series-title":"Note for guidance on harmonization of requirements for influenza vaccines (CPMP\/BWP\/214\/96)","author":"Products","year":"1997"},{"issue":"May (9523)","key":"10.1016\/j.vaccine.2011.08.042_bib0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2011.08.042_bib0130","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"Rumke","year":"2008","journal-title":"Vaccine"},{"issue":"September (9540)","key":"10.1016\/j.vaccine.2011.08.042_bib0135","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(06)69294-5","article-title":"Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial","volume":"368","author":"Lin","year":"2006","journal-title":"Lancet"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2011.08.042_bib0140","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1056\/NEJMoa073121","article-title":"A clinical trial of a whole-virus H5N1 vaccine derived from cell culture","volume":"358","author":"Ehrlich","year":"2008","journal-title":"N Engl J Med"},{"issue":"December (9400)","key":"10.1016\/j.vaccine.2011.08.042_bib0145","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(03)15014-3","article-title":"Safety and antigenicity of whole virus and subunit influenza A\/Hong Kong\/1073\/99 (H9N2) vaccine in healthy adults: phase I randomised trial","volume":"362","author":"Stephenson","year":"2003","journal-title":"Lancet"},{"issue":"July (1\u20132)","key":"10.1016\/j.vaccine.2011.08.042_bib0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virusres.2004.02.029","article-title":"Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use","volume":"103","author":"Hehme","year":"2004","journal-title":"Virus Res"},{"issue":"July (Suppl 1)","key":"10.1016\/j.vaccine.2011.08.042_bib0155","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"issue":"July (33)","key":"10.1016\/j.vaccine.2011.08.042_bib0160","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","article-title":"Eleven years of Inflexal((R)) V \u2013 a virosomal adjuvanted influenza vaccine","volume":"27","author":"Herzog","year":"2009","journal-title":"Vaccine"},{"issue":"February (13\u201314)","key":"10.1016\/j.vaccine.2011.08.042_bib0165","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","article-title":"Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans","volume":"19","author":"Treanor","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.08.042_bib0170","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1371\/journal.pone.0001401","article-title":"Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine","volume":"3","author":"Baras","year":"2008","journal-title":"PLoS ONE"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.08.042_bib0175","first-page":"1252","article-title":"Reproducibility of serologic assays for influenza virus A (H5N1)","volume":"15","author":"Stephenson","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"November (48)","key":"10.1016\/j.vaccine.2011.08.042_bib0180","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1016\/j.vaccine.2009.08.056","article-title":"Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase","volume":"27","author":"Tsai","year":"2009","journal-title":"Vaccine"},{"issue":"November (50)","key":"10.1016\/j.vaccine.2011.08.042_bib0185","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2011.08.042_bib0190","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/597401","article-title":"Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial","volume":"48","author":"Wu","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2011.08.042_bib0195","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-0346-0279-2_9","article-title":"Correlates of protection against influenza","author":"Montomoli","year":"2011","journal-title":"Influenza Vaccines Future"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0205","unstructured":"CHMP. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application 2008."},{"issue":"March (10)","key":"10.1016\/j.vaccine.2011.08.042_bib0210","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.08.042_bib0215","unstructured":"WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases; 2007 [cited 2011 0316]. Available from: http:\/\/www.who.int\/csr\/disease\/avian_influenza\/guidelines\/RecAIlabtestsAug07.pdf."},{"issue":"June (11)","key":"10.1016\/j.vaccine.2011.08.042_bib0220","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T13:54:21Z","timestamp":1592834061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11012837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":44,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11012837"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}